感染旋毛虫小鼠的细胞因子和T淋巴细胞亚群的动态变化

目的：探讨感染旋毛虫小鼠的细胞免疫调节作用。方法：将小鼠分为重感染组、轻感染组及对照组，于感染后不同时间随机取脾细胞制备悬液，分别以旋毛虫抗原及ＣｏｎＡ刺激后，检测白细胞介素ＩＬ－２及ＩＬ－６的活性、ＩｇＧ抗体水平以及ＣＤ４＋、ＣＤ８＋Ｔ细胞含量。结果：感染早期脾细胞以ＩＬ－２的分泌为主，而感染晚期以ＩＬ－６为主，重感染组比轻感染组的ＩＬ－２与ＩＬ－６分泌多。感染后７ｄ血清中出现ＩｇＧ抗体，２８－３５ｄ达高峰；感染后１４－２１ｄ，ＣＤ４＋含量逐渐减少，２１ｄ后又逐渐上升，而ＣＤ８＋的含量却持续增多。结论：感染４ｗｋ后，ＩＬ－６的诱生水平持续增高，可能对旋毛虫病的获得性免疫起重要作用。ＩＬ－２活性与ＣＤ８＋Ｔ细胞百分率的增高，可能提示Ｔｈ１产生的细胞因子促进ＩＬ－２活性与ＣＤ８＋Ｔ细胞活化。     

呋喃唑酮与胶体铋剂联合应用治疗幽门螺杆菌相关性胃炎的疗效观察

应用胶体铋剂（ＣＢＳ）与不同剂量的呋喃唑酮（Ｆ）联合治疗Ｈｐ阳性慢性胃炎患者。１７３例病人随机分为５组（ＣＢ８组、Ｆ０．２组、ＣＢＳ＋Ｆ０．２组、ＣＢＳ＋Ｆ０．１组、ＣＢＳ＋Ｆ０．０５组）服药４周（ＣＢＳ４周＋Ｆ２周），Ｈｐ根除率分别为２３．３％、５９．３％、１００％、９１．３％和６１．９％；活动性胃炎消退率分别为１４．０％、４８．１％、７０．９％、８６．７％和５３．３％；副作用发生率分别为４．６％、２１．８％、２３．５％、７．１％和１４．８％。ＣＢＳ＋Ｆ０．２及ＣＢＳ＋Ｆ０．１组Ｈｐ根除率及活动性胃炎消退率均显著高于其它三组（Ｐ＜００５）；且ＣＢＳ＋Ｆ０．１与ＣＢＳ＋Ｆ０．２疗效相当，Ｈｐ根除率可达９０％以上，副作用程度明显减轻，是较理想的根除Ｈｐ方案。     

活化剂HYP协同“425”制剂的抗日本血吸虫虫卵肉芽肿病变免疫效应机理的研究

采用流式细胞仪测定Ｔ细胞亚群和脾脏Ｂ淋巴细胞电泳对应用活化剂ＨＹＰ协同“４２５”制剂的日本血吸虫感染的ＢＡＬＢ／ｃ小鼠进行细胞和体液免疫机能测定，并与单一用“４２５”制剂和感染对照动物进行比较。实验结果表明，ＨＹＰ协同“４２５”制剂应用后２ｗｋ，相当于感染后６ｗｋ，ＣＤ４＋／ＣＤ８＋淋巴细胞亚群的比值为６．８２，显著高于后两组的１．８７和１．７９，脾脏中Ｂ淋巴细胞总频率达７５％，高于单一用“４２５”制剂和感染对照组的６２．５％和６４．５％，特异性抗体水平（ＯＤ均值）为０．５５±０．１１，分别高于后两组的０．３５±０．０３和０．３７±０．０７。应用后３～４ｗｋ，相当于感染后７～８ｗｋ，ＣＤ４＋／ＣＤ８＋比值为１．９８～３．４７，后两组则分别为１．３２～１．５９和１．４８～１．７０，Ｂ淋巴细胞数３组均相近，但前组抗体水平（ＯＤ均值）的升高率（８２．２２％～９１．１８％）仍高于后两组。由此提示，活化剂ＨＹＰ协同“４２５”制剂诱导出的抗日本血吸虫虫卵肉芽肿的免疫效应，显著减弱血吸虫虫卵肉芽肿病变是与增强其细胞和体液免疫功能密切相关，具有明显的理论意义，且为进一步探索抗肉芽肿病变提供了重要依据     

环孢素A治疗难治性肾病综合征

目的研究环孢素Ａ（ＣｓＡ）治疗难治性肾病综合征的临床疗效并探讨其机制。方法对３０例肾上腺皮质激素依赖或抵抗的肾病综合征（ＮＳ）患者联合使用了（ＣｓＡ，５ｍｇ·ｋｇ－１·ｄ－１）和泼尼松（３０ｍｇ／ｄ）治疗，并测定了ＣｓＡ治疗前后病人的血生化指标、免疫指标及２４小时尿蛋白排出量。结果２４小时尿蛋白排出量由治疗前的平均７．６７±３．００ｇ／２４ｈ降至治疗后第１、２、３个月的４．９３±３．６４ｇ／２４ｈ、３．５２±２．９４ｇ／２４ｈ、２．２３±１．６０ｇ／２４ｈ；血浆白蛋白由治疗前２７．３±６．４ｇ／Ｌ升至３０．９±８．８ｇ／Ｌ、３４．３±７．６ｇ／Ｌ、３６．０±７．２ｇ／Ｌ；治疗前后血肌酐、ＢＵＮ、尿酸、ＣＤ４／ＣＤ８和可溶性白细胞介素２（ＩＬ２）受体无明显变化，而治疗２个月后外周血单个核细胞产生血清ＩＬ２显著下降。治疗后激素抵抗组ＮＳ完全缓解、部分缓解和无效分别为２２．７％，５０．０％和２７．３％；在激素依赖组分别为５７．１％，４２９％和０。有５例患者因肝肾功能损害或严重腹泻而停用ＣｓＡ。结论本研究提示ＣｓＡ联合小剂量皮质激素治疗难治性肾病综合征，尤其是激素依赖的患者是安全和有效的。     

雌激素对绝经后妇女冠心病治疗作用的观察

目的探索雌激素对绝经后妇女冠心病的防治机制及疗效。方法将１０８例绝经１年以上的女性冠心病患者随机分为三组（各３６例），甲组口服结合雌激素（倍美力）０．６２５ｍｇ１／ｄ，乙组口服７甲基异炔诺酮（利维爱）２．５ｍｇ１／ｄ，丙组口服安慰剂１片１／ｄ，于服药前及服药后第３、６个月末检测血脂谱及ＥＣＧ，并记录心绞痛发作情况。结果倍美力治疗后可使胆固醇（ＴＣ）降低１２．８％，甘油三酯（ＴＧ）降低１７．０％，低密度脂蛋白胆固醇（ＬＤＬＣ）降低２９．０％，高密度脂蛋白胆固醇（ＨＤＬＣ）上升１４６％。利维爱治疗后ＴＣ降低８．７％，ＴＧ降低１５．６～３３．８％、ＨＤＬＣ降低１９．７～２８．３％（Ｐ值均＜００１），ＬＤＬＣ无显著变化。倍美力及利维爱治疗第３、６个月后对心绞痛症状的总有效率分别为９０９％、９３５％和８３．３％和９３．１％，对ＥＣＧ缺血性改变的总有效率分别为７６．７％、８２．１％和７８．６％、８１４％，两种药物对妇女冠心病的心肌缺血疗效差异无显著性（Ｐ＞０．０５）。结论雌激素替代治疗可显著改善绝经后妇女冠心病患者的异常血脂及心肌缺血     

NIDDM患者ApoE基因型与大,微血管病变关系的研究

目的 研究ＮＩＤＤＭ患者ＡｐｏＥ基因型与大，微血管病变的关系。方法 采用ＡＲＭＳ技术检测２００例ＮＩＤＤＭ患者漱口水ＤＮＡ ＡｐｏＥ基因型，结果 （１）∈４／３∈４／４组ＣＡＤ发生率为７０．８％，显著高于∈３／３组４８．４％，和∈２／２∈３／２组４３．５；ＣＶＤ及ＰＶＤ亦存在这种趋势；∈４／３∈４／４组任何证据大血管病变发生率为７５％，显著高于∈３／３组５１．６％和∈２／２∈３／２组４７．８％。     

中药自拟方对18例HIV感染者近期疗效的的初步观察

目的 探讨中药对人类免疫缺陷病毒（ＨＩＶ）感染者及患者的作用。方法 体外测定中药的保护浓度，临床治疗ＨＩＶ携带者及艾滋病患者，考核指标为ＣＤ４计数及病毒核酸酸载量，结果 体外试验显示５０％细胞保护平均浓度为０．２２５ｍｇ／ｍｌ，治疗后，ＣＤ＾＋４上升１１％～５０％者４例，〉５１％者８例，〈１０％者４例，病毒载量有３例眼药后完全降至正常，２例下降９０％以上，结论 中药可能成为一种有潜力的抗艾滋病药物     

胸腺肽α1治疗重症肝炎的免疫调节研究

为了解日达仙的免疫调节作用,选取１８例下肝炎病人用日达仙（Ｔα１）治疗,并在治疗前后检测内毒素（ＬＳＰ）、肝瘤坏死因子（ＴＮＦ）、白细胞介素２受体（ＩＬ－２Ｒ）、白细胞介素４（ＩＬ－４）、白细胞介素６（ＩＬ－６）、及Ｔ细胞亚群（ＣＤ８＾＋、ＣＤ４＾＋）。结果治疗前ＬＳＰ、ＴＮＦ、ＩＬ－２Ｒ、ＩＬ－６、ＣＤ８＾＋均增高９Ｐ〈０．０１）,而ＩＬ－４及ＣＤ４＾＋降低。经Ｔα１治疗后ＬＳＰ、ＴＦ、ＩＬ－２     

芪黄冲剂对慢性乙型肝炎患者免疫功能的影响

目的：观察芪黄冲剂对慢性乙型病毒性肝炎免疫功能的影响。方法：治疗组以芪黄冲剂治疗,对照组以乙肝清热解毒冲剂合乙肝养阴活血冲剂治疗。两组患者采用间接免疫荧光法检测,治疗前后免疫球蛋白ＩｇＧ、ＩｇＭ、ＩｇＡ、Ｔ淋巴细胞亚群ＣＤ３＾＋、ＣＤ４＾＋、ＣＤ８＾＋、ＣＤ４＾＋／ＣＤ８＾＋、ＩＬ－２、ＩＬ－６、ＴＮＦ、ＮＫ。结果：芪黄冲剂具有益气活血,滋养肝肾兼以清热解毒作用,能升高ＣＤ４＾＋、ＮＫ细胞,提高ＣＤ４＾＋／ＣＤ８＾＋比值及ＩＬ－２水平,降低ＣＥ８＾＋,尤其对ＣＤ４＾＋、ＣＤ４＾＋／ＣＤ８＾＋、ＮＫ细胞以及ＩＬ０２的调整作用优于对照组（Ｐ〈０．０５￣０．０１）,能显著降低ＩＬ－６及ＴＮＦ水平（Ｐ〈０．０５￣０．０１）。同时还能降低ＩｇＧ、ＩｇＭ、ＩｇＳ,其中对ＩｇＡ的降低作用显著优于对照组。结论：芪黄冲剂不仅具有     

中药自拟方对18例HIV感染者近期疗效的初步观察

目的探讨中药对人类免疫缺陷病毒（ＨＩＶ）感染者及患者的作用。方法体外测定中药的保护浓度,临床治疗ＨＩＶ携带者及艾滋病患者,考核指标为ＣＤ４＋计数及病毒核酸载量。结果体外试验显示５０％细胞保护平均浓度为０．２２５ｍｇ／ｍｌ,治疗后,ＣＤ４＋上升１１％～５０％者４例,＞５１％者８例,＜１０％者４例。病毒载量有３例服药后完全降至正常,２例下降９０％以上。结论中药可能成为一种有潜力的抗艾滋病药物。     

河南省经血感染艾滋病病人机会感染疾病谱分布

目的探讨河南省经血感染艾滋病(AIDS)病人机会感染疾病谱的分布状况。方法对2000年7月-2010年12月,在郑州市第六人民医院治疗的2 027例AIDS病人的临床资料进行回顾性分析。结果 (1)2 027例病人共发生3 613例次机会感染,主要为呼吸系统(76.17%)和消化系统感染(47.95%),最常见的机会感染依次为细菌性肺炎(35.22%)、口腔念珠菌感染(32.17%)、肺结核(20.37%)、肺孢子菌肺炎(PCP)(15.29%)。(2)其中的711例病人按CD4细胞计数不同分5组,PCP和各种感染性腹泻在CD4<50个/mm3组所占比例最高(30.82%、23.29%),口腔念珠菌感染和隐球菌脑膜炎在50～99个/mm3组比例最高(33.63%、6.19%),肺结核在100～199个/mm3组比例最高(28.68%),各种痒疹在200～349个/mm3组比例最高(17.24%)。按合并机会感染数量不同分5组,各组CD4细胞计数相比差异有统计学意义(P<0.05)。结论 AIDS病人机会感染疾病谱因国家、地区和人种不同,甚至传播途径不同有所差异,各种机会感染的发病比例在不同CD4水平有所不同;随着CD4细胞计数下降,发生机会感染的数量逐渐增加。     

Immunological responses in the aged with bacterial infection

The effect of bacterial infection on immunologic parameters was investigated in the elderly, with special reference to natural killer (NK) cells. The parameters studied were percentage of lymphocyte subsets, interleukin-2 concentration and NK cytotoxicity. In the bacterial infection group (n = 15), there were several changes in the immunological parameters when compared with the healthy aged control group (n = 42): decreased in the lymphocyte number, decreased percentage of CD4+ cells resulting a lower CD4+/CD8+ ratio, diminished NK activity without a change in the percentage of NKH-1+ cells, and increased CD25+ cells which consisted mainly of CD25+ NKH-1+ cells. These changes recovered in all patients examined (n = 7) following resolution of the infection. Decreased NK activity, although transient, may be related to be susceptible to infection or to be prolonged course of infectious diseases in the elderly.     

Bacterial pneumonia in hospitalized patients with HIV infection: the Pulmonary Complications, ICU Support, and Prognostic Factors of Hospitalized Patients with HIV (PIP) Study

STUDY OBJECTIVES: To describe the causative organisms and factors associated with bacterial pneumonia and to assess its impact on the outcome of hospitalized patients with HIV. DESIGN: Prospective, observational. SETTING: A university-affiliated medical center. METHODS: We included 1,225 consecutive hospital admissions, from April 1995 through March 1998, of 599 adults with HIV. We collected data on APACHE II (acute physiology and chronic health evaluation II) score, leukocyte and CD4+ lymphocyte counts, length of hospital stay, ICU admission rate, and case-fatality rate. Chest radiographs and laboratory results were reviewed. The presence of bacterial pneumonia was noted. RESULTS: Bacterial pneumonia was diagnosed in 111 hospitalizations (9%): 80 (72%) were community-acquired infections. The CD4+ lymphocyte count was lower (median, 38 vs 66/microL, p = 0.0027), APACHE II score higher (17 vs 13, p < 0. 0001), length of hospital stay longer (median, 6 vs 4), and ICU admission (28% vs 9%) and case-fatality rates (21% vs 4%) higher in patients with bacterial pneumonia compared with those without bacterial pneumonia. The most common pathogen was Pseudomonas aeruginosa (32 admissions), followed by Streptococcus pneumoniae (22 admissions), Staphylococcus aureus (16 admissions), and Haemophilus influenzae (11 admissions). Thirty-three (30%) of the pneumonias were bacteremic. Bacteremia was more common in pneumococcal than in pseudomonal pneumonia (95% vs 9%, p < 0.0001). Compared with patients with pneumococcal pneumonia, patients with pseudomonal pneumonia had lower leukocyte and CD4+ lymphocyte counts, longer hospital stay, and similar case-fatality rate. CONCLUSIONS: P aeruginosa is becoming a common cause of both community-acquired and nosocomial bacterial pneumonia in hospitalized patients with HIV, especially in those with low leukocyte and CD4+ lymphocyte counts.     

云南省HIV／AIDS病人早期抗病毒治疗的有效性和安全性分析

目的评价云南省艾滋病病毒（HIV）感染者／艾滋病（AIDS）病人（HIV／AIDs病人）早期抗反转录病毒治疗（ART）的有效性和安全性。方法对云南省2011年8月至2012年8月期间开始ART的病人,按照基线CD4淋巴细胞（CD4细胞）计数水平分A、B两组,A组为基线CD4细胞计数〉350／±的病人（早期治疗组）,B组为基线CD4细胞计数≤350／μL．的病人（延迟治疗组）。比较两组病人治疗满1年后的队列保持情况、治疗效果、治疗期间病人的不良反应和机会性感染发生等情况。结果两组9810例病人治疗满1年后,在队列保持方面,A组病人坚持治疗的比例（在治率）为88．0％（1712／1946）,高于B组的84．9％（6674／7864）;死亡率A组（1．2％）低于B组（5．7％）;在治疗效果方面,两组的HIV病毒载量抑制比例差异无统计学意义（P〉0．05）,两组病人中．HIV病毒载量〈C400拷贝／mL病人所占比例,分别为90．4％和91．2％;治疗6个月和12个月时,与基线CD4细胞计数相比,A组的增幅（4．32％）（治疗前后CD4细胞差值的比较）低于B组（10．27％）,P〈0．01,但A组病人仍然获得比B组较高的CD4细胞平均值;在机会性感染和不良反应方面,A组的发生比例（4．3％和20．9％）均低于B组（10．3％和24．3％）,P〈0．01。结论云南省HIV／AIDS病人早期治疗12个月能够获得良好的有效性和安全性,初步实现了减少HIV相关的发病率和死亡率、非艾滋病相关疾病的发病率和死亡率和改善生活质量的抗病毒治疗总体目标。     

Flow cytometric study of lymphocyte subsets in patients at different stages of colorectal carcinoma

PURPOSE: The evaluation of lymphocyte subsets by using monoclonal antibodies in neoplastic patients has provided different results, partly in relation to the stage of the disease. Therefore, as a preliminary study of cancer patients treated with immunomodulating drugs, an analysis of lymphocyte subsets was performed in colorectal carcinoma patients. METHODS: In this study, a flow cytometric evaluation of lymphocyte subsets was performed in 33 patients affected by colorectal carcinoma, with or without metastases. RESULTS: A significant reduction of hemoglobin concentrations and hematocrit was observed in all of these subjects, associated with an evident increase of white blood cells, platelets, and HLA DR-positive T lymphocytes, whereas CD 3-CD 4-positive and CD 20-positive lymphocyte concentrations were decreased. Subjects without metastases showed an evident decrease of hemoglobin concentrations and an increase of white blood cells, platelets and CD 3-HLA DR-positive lymphocytes, while patients with disseminated disease also had reduced mean values of hematocrit, red blood cells, CD 3-CD 4-positive, and CD 20-positive lymphocytes. CONCLUSIONS: The main differences between colorectal carcinoma patients with or without metastases were represented by a decrease of red blood cells, CD 3-CD 4-positive, and CD 20-positive lymphocyte concentrations in the latter group.     

He Jie Tang in the treatment of chronic hepatitis B patients

AIM: To explore the effect of He Jie Tang (decoction for medication) on serum levels of T lymphocyte subsets, NK cell activity and cytokines in chronic hepatitis B patients. METHODS: Eighty-five patients with chronic hepatitis B were divided randomly into two groups. Fifty patients in group Ⅰ were treated with He Jie Tang (HJT) and 35 patients in group Ⅱ were treated with combined medication. The levels of T-lymphocyte subsets (CD3+, CD4+, CD8+), NK cell activity, cytokines (TNF-α, IL-8, sIL-2R) were observed before and after the treatment. Another 20 normal persons served as group 3. RESULTS: The level of CD4+ cells and NK cell activity were lower, whereas the level of CD8+ cells in patients was higher than that in normal persons (t = 2.685, 3.172, and 2.754 respectively; P<0.01). The levels of TNF-α, IL-8, and sIL-2R in chronic hepatitis B patients were higher than those in normal persons (t = 3.526, 3.170, and 2.876 respectively; P<0.01). After 6 months of treatment, ALT, AST, and TB levels in the two groups were obviously decreased (t = 3.421, 3.106, and 2.857 respectively; P<0.01). The level of CD4+ cells and NK cell activity were increased whereas the level of CD8+ cells decreased (t = 2.179, 2.423, and 2.677 respectively; P<0.05) in group Ⅰ. The levels of TNF-α, IL-8, and sIL-2R in group I were decreased significantly after the treatment (t = 2.611, 2.275, and 2.480 respectively; P<0.05) but had no significant difference in group Ⅱ after the treatment (t = 1.906, 1.833, and 2.029 respectively; P>0.05). The total effective rate had no significant difference between the two groups (X2 = 2.882, P>0.05) but the markedly effective rate was significantly different between the two groups (X2 = 5.340, P<0.05). CONCLUSION: HJT is effective in treating chronic hepatitis B. HJT seems to exert its effect by improving the cellular immune function and decreasing inflammatory cytokines in chronic hepatitis B patients. The function of HJT in protecting liver function in the process of eliminating virus needs to be further studied.     

干细胞移植后合并巨细胞病毒感染时淋巴细胞亚群变化

目的　研究异基因外周血干细胞移植 (PBSCT)后早期巨细胞病毒 (CMV)活动性感染时淋巴细胞亚群变化及其意义 ,探讨活动性CMV感染对免疫的影响。方法　根据CMV感染情况 ,将 2 7例早期PBSCT受者分为症状性感染、无症状活动性感染以及同期未出现活动性感染 3组 ,5 1例正常人作为对照组 ,用流式细胞仪测定其淋巴细胞表面CD3 、CD4、CD8、CD16、CD56、CD19、CD2 8的表达 ,比较各组间的差异。结果　PBSCT后早期CD+ 4 T和B细胞数量显著低于正常人 (P值均 <0 0 1) ;2 7例受者中无活动性CMV感染 5例、无症状活动性CMV感染 10例和症状性CMV感染 12例。上述 3组病人的平均CD+ 4 T细胞计数 (× 10 6/L)分别为 32 8± 2 0 3、2 39± 2 18和 199± 92 ;CD+ 8T细胞计数 (× 10 6/L)分别为 4 0 0± 380、2 6 7± 2 0 6和 6 0 3± 4 6 1;CD+ 4 CD+ 2 8的功能细胞亚群的比例分别为 (89 2± 8 9) %、(84 2±10 1) %和 (6 3 5± 11 4 ) % ;自然杀伤 (NK)细胞比例分别为 (16 2± 11 1) %、(2 9 3± 9 9) %和 (19 2±10 2 ) %。与无活动性CMV感染者相比 ,无症状CMV活动性感染者除NK细胞升高外 (P <0 0 1) ,其他指标差异无显著性 ;而症状性CMV感染者和无症状CMV感染者相比 ,其CD+ 4 T细胞数量显著减少(P <0 0 1) ,CD+ 8T     

艾迪注射液对II、III期结肠癌患者的免疫调节作用以及临床疗效影响

摘 要：目的 观察艾迪注射液对II、III期结肠癌患者临床疗效的影响以及免疫调节作用。方法 选择2014年1月至2016年2月我院治疗的II、III期结肠癌患者154例,采用数字表法分为对照组和观察组,每组77例。对照组：奥沙利铂（120mg/m2,静滴2h）+亚叶酸钙（200mg/m2,静滴2h）+ 5-氟尿嘧啶（2400mg/m2,静滴4~6h）,3周为一疗程。观察组在对照组基础上加用艾迪注射液,50mL静滴,每天 1次,10d为1疗程,共4疗程。流式细胞仪检测患者治疗前后外周血CD4+和CD8+ T淋巴细胞的比例变化。临床疗效按世界卫生组织 (WHO)实体瘤疗效评定标准。远期临床疗效评价：疗程结束后随访1年。比较两组的复发转移率和死亡率。结果 治疗前两组CD4+、CD8+ T淋巴细胞的比例和CD4+/ CD8+比值无显著性差异（P>0.05）,治疗后观察组CD4+T淋巴细胞比例和CD4+/ CD8+比值显著高于对照组（P<0.05）,治疗后观察组CD8+T淋巴细胞比例显著低于对照组（P<0.05）。观察组近期临床有效率为84.4%（65/77）,显著高于对照组的67.5%（52/77）（P<0.05）,控制率为93.5%（62/77）,显著高于对照组的81.8%（63/77）（P<0.05）。观察组1年后复发转移率为18.2%（14/77）,显著低于对照组的32.5%（25/77）（P<0.05）,观察组１年生存率为88.3%（68/77）,显著高于对照组的75.3%（58/77）（P<0.05）。结论 艾迪注射液辅助治疗II、III期结肠癌,可以提高CD4+T淋巴细胞比例和CD4+/ CD8+比值,增强免疫功能,提高患者的远期临床疗效。     

CIK维持治疗中晚期肺癌的临床观察及影响因素分析

目的观察细胞因子诱导的杀伤细胞对维持治疗中晚期肺癌患者的临床疗效。方法选取49例接受化疗联合CIK进行治疗的中晚期肺癌患者作为实验组,49例同期接受单纯化疗的中晚期肺癌患者作为对照组。结果治疗后的2、4和8周实验组CD+3、CD+4T细胞、CD+4/CD+8比值以及细胞因子IL-2和IFN-γ均比同期对照组显著增加;治疗后,实验组的有效率为48.97%,控制率为89.80%,对照组的有效率为8.16%,控制率为51.02%;实验组中癌症类型以及是否合并转移对临床疗效影响显著,各结果差异显著。结论细胞因子诱导的杀伤细胞能够显著提高中晚期肺癌患者的临床疗效。     

骨髓间质干细胞对系统性红斑狼疮患者调节性T细胞的免疫调节作用

目的探讨自体与异体骨髓间质干细胞（MSCs）对系统性红斑狼疮（SLE）患者调节性T细胞的免疫调节作用。方法用Percoll密度梯度离心法从14例SLE患者和15例健康人骨髓中分离MSCs,同时用免疫磁珠（MACS）分离SLE患者外周血CD4^＋CD25^＋T细胞。将SLE患者外周血分离的淋巴细胞或CD4^＋CD25^＋T细胞与自体、异体MSCs共培养,观察MSCs对淋巴细胞及CD4^＋CD未T细胞增殖的影响,同时测CD4^＋CD25^＋T细胞分泌IL-10、转化生长因子（TGFβ）水平及细胞毒T淋巴细胞相关抗原4（CTLA-4）表达。结果自体与异体MSCs均抑制淋巴细胞增殖,其抑制率分别为56．32％、65．46％。MSCs以数量依赖性方式促进纯化CD4^＋CD25^＋T细胞增殖,分泌IL-10、TGFβ水平升高。结论MSCs可纠正SLE活动时CD4＋CD25^＋T细胞免疫缺陷,并抑制淋巴细胞过度活化,可能在自身免疫病的外周血造血干细胞和间质干细胞共移植或MSCs单独移植中发挥重要的免疫调节作用。